Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

Fig. 2

Activation of pERBB receptors in FGFR inhibitor-resistant bladder cancer cell lines. A SW780 and RT4 parental (PAR) and Resistant (RS) lines were grown in fresh medium for 24 h without exposure to BGJ398, and cell lysates hybridised to phospho-RTK arrays. Hybridisation signals at the corners serve as controls. B Western blot analysis confirming the increase in pERBB3 in SW780 and RT4 parental (PAR) and FGFR inhibitor-resistant (RS) cell lines. Data shown are from a representative experiment

Back to article page